Oxford Biomedica Plc (United Kingdom) (OXB:LN)

Oxford BioMedica Plc (United Kingdom) (OXB:LN)

Health Care/Biotechnology Price: 1,560.00 GBX Report Date: September 24, 2021 Business Description and Key Statistics

Oxford Biomedica developes gene and cell therapy with a focused Current YTY % Chg on lentiviral vector research, development and bioprocessing. Co. has built a lentiviral vector delivery system, LentiVector® platform, Revenue LFY (M) 64 -4.1 which Co. utilizes to develop in vivo and ex vivo products both in- EPS Diluted LFY -0.22 house and with partners. Co. has a portfolio of gene and cell therapy product candidates in the areas of oncology, Market Value (M) 1,199 ophthalmology, liver and CNS disorders. Co.'s partnered products includes AXO-Lenti-PD, which is a gene-based treatment for Shares Outstanding LFY (000) 76,859 Parkinson's disease; SAR422459, which is a gene-based therapy Book Value Per Share 0.98 for the treatment of Stargardt disease; and SAR421869, which is a gene-based therapy for the treatment of Usher syndrome 1B. EBITDA Margin % -13.60 Net Margin % -24.2 Website: www.oxb.com Long-Term Debt / Capital % 0.0 ICB Industry: Health Care Dividends and Yield TTM 0.00 - 0.00% ICB Subsector: Biotechnology Payout Ratio TTM % 0.0 Address: Windrush Court;Transport Way Oxford 60-Day Average Volume (000) 146 GBR 52-Week High & Low 1,634.00 - 783.00 Employees: 554 Price / 52-Week High & Low 0.95 - 1.99

Price, Moving Averages & Volume

1,679.9 1,679.9 Oxford BioMedica Plc (United Kingdom) is currently trading at 1,560.00 which is 10.1% 1,553.8 1,553.8 above its 50 day moving average price of 1,417.08 and 1,427.7 1,427.7 35.4% above its 200 day moving average price of 1,151.84. 1,301.6 1,301.6 OXB:LN is currently 4.5% below its 52-week high price of 1,175.5 1,175.5 1,634.00 and is 99.2% above its 52-week low price of 1,049.4 1,049.4 783.00. Over the past 52- weeks, OXB:LN is up 90.5% while on a calendar year-to- 923.3 923.3 date basis it is up 51.5%.

The Relative Strength Index 797.2 797.2 (RSI) indicator for OXB:LN is currently 58.69. An RSI value 671.1 671.1 of 70 and above is considered 10/20 11/20 12/20 1/21 2/21 3/21 4/21 5/21 6/21 7/21 8/21 9/21 overbought and 30 and below Volume (000) oversold. 1,979 1,979

1,484 1,484

990 990

495 495 Mean (164.04) 0 0 10/20 11/20 12/20 1/21 2/21 3/21 4/21 5/21 6/21 7/21 8/21 9/21

Price Price (50-Day Simple Moving Average) Price (200-Day Simple Moving Average)

Health Care/Biotechnology Price: 1,560.00 GBX Report Date: September 24, 2021 Price Performance, Technical Indicators & Risk Metrics

Difference Price Performance % Change vs FTSE 350 Technical Indicators 1-Day % -3.58 -3.10 50-Day Average Price 1417.08 1-Week % 9.09 8.83 Price / 50-Day Average 1.10 4-Week % 7.59 9.01 200-Day Average Price 1151.84 52-Week % 90.48 66.13 Price / 200-Day Average 1.35 RSI - Relative Strength Index 58.69 Quarter-to-Date % 20.00 18.87

Year-to-Date % 51.46 41.24 Risk Metrics Last Month % 11.26 9.34 Price Volatility 56.20 Last Quarter % 36.55 31.88 Sharpe Ratio 0.22 Last Calendar Year % 59.69 72.68 Sortino Ratio 0.52

5-Year Price Performance vs. FTSE 350

Oxford BioMedica Plc (United Kingdom) Current: 2.25 CAGR: 27.7% Over the past five years, FTSE 350 Index Current: 1.18 CAGR: 3.4% Oxford BioMedica Plc (United Kingdom)'s stock price is up 2.3 2.3 124.8% which is 106.4% above the FTSE 350 Index OXB:LN performance of 18.4% over the 2.2 2.2 same period. Oxford BioMedica Plc (United 2.0 2.0 Kingdom)'s cumulative annualized growth rate (CAGR) over the five year 1.9 1.9 period has been 27.7% while that of the FTSE 350 Index has been 3.4%. 1.8 1.8 Over the past year, Oxford 1.6 1.6 BioMedica Plc (United Kingdom)'s stock price performance of 90.5% has 1.5 1.5 outperformed that of the FTSE 350 Index by 66.1%. On a 1.3 1.3 year-to-date basis, Oxford BioMedica Plc (United Kingdom)'s stock price 1.2 ^NMX:LN 1.2 performance of 51.5% has outperformed the FTSE 350 Index by 41.2%. 1.1 1.1 Over the past week, Oxford 0.9 0.9 BioMedica Plc (United Kingdom)'s stock price performance of 9.1% has 0.8 0.8 outperformed that of the FTSE 350 Index by 8.8%. 0.7 0.7 2017 2018 2019 2020 2021 2022

Health Care/Biotechnology Price: 1,560.00 GBX Report Date: September 24, 2021 Growth and Profitability Metrics

5-Year 10-Year Historical Growth 3-Year 5-Year 10-Year Profitability Current Average Average Revenues % 32.1 36.3 12.9 Gross Margin % 44.2 68.8 Revenues Per Share % 341.7 152.5 38.4 EBITDA Margin % -13.6 -72.4 EBITDA % -4.4 98.2 -4.8 Pre-Tax Margin % -32.6 -93.4 EPS Diluted % -100.0 -100.0 -42.3 Net Margin % -24.2 -117.6 Free Cash Flow % -100.0 -100.0 -100.0 Return on Equity % -34.5 -57.6 Cash from Operations % 88.2 89.7 -99.9 Return on Capital % -34.5 -49.9 Book Value % 522.2 155.8 38.2 Return on Assets % -13.5 -38.2

Revenue (M) Oxford BioMedica Plc (United Kingdom)'s cumulative Current: 64.06 Median: 50.83 High: 66.78 Low: 27.78 CAGR: 32.1% annualized revenue growth 74.6 74.6 66.8 64.1 rate over the charted period is 32.1%. This compares to 58.3 58.3 cumulatative annualized growth of 32.1% over the past 42.1 37.6 42.1 3 years. 27.8 25.8 25.8 2016 2017 2018 2019 2020 2021 Oxford BioMedica Plc (United EPS Diluted Kingdom)'s cumulative Current: -0.22 Median: -0.08 High: 0.11 Low: -0.25 CAGR: -0.1% annualized EPS growth rate 0.18 0.18 over the charted period is 0.11 -0.1%. This compares to 0.03 -0.01 0.03 cumulatative annualized growth of -100.0% over the past 3 years. -0.12 -0.14 -0.12 -0.22 -0.27 -0.27 2016 2017 2018 2019 2020 2021

Net Profit Margin % Oxford BioMedica Plc (United Kingdom)'s net profit margin of Current: -24.18 Median: -21.61 High: 10.37 Low: -871.73 CAGR: -8.2% -24.2% is 127.1% above the 54.5 54.5 period's mean net margin of Mean (-151.31) -151.3%. During the charted -269.0 -269.0 period, the observed net profit margin high and low were -592.4 -592.4 10.4% and -871.7% respectively. -915.8 -915.8 2016 2017 2018 2019 2020 2021 Oxford BioMedica Plc (United Return on Equity % Kingdom)'s return on equity of Current: -34.50 Median: -67.25 High: 53.00 Low: -100.00 CAGR: -12.2% -34.5% is 14.9% above the 60.7 60.7 period's mean return on equity of -49.3%. During the charted 4.5 4.5 period, the observed ROE high and low were 53.0% and Mean (-49.35) -100.0% respectively. -51.5 -51.5

-107.6 -107.6 2016 2017 2018 2019 2020 2021

Health Care/Biotechnology Price: 1,560.00 GBX Report Date: September 24, 2021 Valuation Metrics

5-Year 10-Year 5-Year 10-Year Current Median Median Current Median Median

Price / EPS TTM 99.9 Earnings Yield % -2.87

Price / Sales 17.1 Free Cash Flow Yield % 0.00

Price / Operating Cash Flow 99.9 Dividend Yield % 0.00

Price / Book Value 15.9 Enterprise Value / EBITDA 50.0

Price / EPS TTM Oxford BioMedica Plc (United Kingdom) is trading at 99.90 Current: 99.90 Median: 99.90 High: 99.90 Low: 57.51 CAGR: 0.0% times its EPS generated Median (99.90) 102.0 102.0 during the latest fiscal year. This multiple is equal to the 86.5 86.5 historically observed median of 99.90, while high and low observations have been 99.90 70.9 70.9 and 57.51.

55.4 55.4 2016 2017 2018 2019 2020 2021 Price / Sales Oxford BioMedica Plc (United Kingdom) is trading at a Price Current: 17.07 Median: 8.36 High: 23.44 Low: 5.53 CAGR: 1.6% to Sales ratio of 17.07 based 24.34 24.34 on sales generated during the latest fiscal year. This ratio is 17.77 17.77 above the historically observed median ratio of 8.36, while high and low observations 11.20 11.20 have been 23.44 and 5.53. Median (8.36)

4.63 4.63 2016 2017 2018 2019 2020 2021 Oxford BioMedica Plc (United Price / Book Value Kingdom) is trading at a Price Current: 15.85 Median: 11.83 High: 49.90 Low: 5.14 CAGR: -29.2% to Book ratio of 15.85 based 52.1 52.1 on book value at the latest fiscal year end. This ratio is above the historically observed 35.7 35.7 median of 11.83, while high and low observations have 19.3 19.3 been 49.90 and 5.14. Median (11.83)

2.9 2.9 2016 2017 2018 2019 2020 2021 Oxford BioMedica Plc (United Free Cash Flow Yield % Kingdom) has a Free Cash Current: 0.00 Median: 0.00 High: 0.69 Low: 0.00 CAGR: 0.0% Flow Yield of 0.00% based on 0.7 0.7 free cash flow generated during the latest fiscal year. This value is equal to the 0.5 0.5 historically observed Free Cash Flow Yield of 0.00%, 0.2 0.2 while high and low observations have been 0.69 Median (0.00) and 0.00. 0.0 0.0 2016 2017 2018 2019 2020 2021

Health Care/Biotechnology Price: 1,560.00 GBX Report Date: September 24, 2021 ICB Subsector Peer Comparisons

Price Change Year to Date % Price Change Last Calendar Year % -75.6 -34.8 5.9 46.6 87.3 -66.9 -33.8 -0.6 32.6 65.7

Bavarian Nordic A/S 79.9 Oxford BioMedica Plc (United Kingdom) 59.7

Nordic Nanovector ASA 53.6 Genus Plc 32.1

Oxford BioMedica Plc (United Kingdom) 51.5 Abcam PLC 14.6

BioArctic AB 45.1 Bavarian Nordic A/S 9.2

Genus Plc 32.9 Novozymes A/S 7.1

Novozymes A/S 32.5 Peer Group Average 5.7

Peer Group Average 29.8 BioArctic AB 1.2

Abcam PLC -2.7 MorphoSys AG -28.6

MorphoSys AG -54.7 Nordic Nanovector ASA -49.9

-75.6 -34.8 5.9 46.6 87.3 -66.9 -33.8 -0.6 32.6 65.7

Price / EPS TTM Price / Book Value 0.0 26.0 51.9 77.9 103.8 0.0 4.1 8.3 12.4 16.5

Oxford BioMedica Plc (United Kingdom) 99.9 Oxford BioMedica Plc (United Kingdom) 15.9 XSpray Pharma AB 99.9 BioArctic AB 12.5 Nordic Nanovector ASA 99.9 Novozymes A/S 11.6 BioArctic AB 99.9 Nordic Nanovector ASA 10.8 BerGenBio ASA 99.9 Peer Group Average 7.4 Abcam PLC 99.9 Genus Plc 7.1 Genus Plc 90.1 BerGenBio ASA 6.0 Peer Group Average 77.3 Abcam PLC 5.4 Bavarian Nordic A/S 66.6 Bavarian Nordic A/S 4.0 Novozymes A/S 46.6 Lonza Group AG 3.3 Lonza Group AG 26.2 XSpray Pharma AB 2.6 MorphoSys AG 21.4 MorphoSys AG 2.2 0.0 26.0 51.9 77.9 103.8 0.0 4.1 8.3 12.4 16.5

EPS 5-Year Growth Rate % Revenue 5-Year Growth Rate % -122.0 -79.1 -36.2 6.6 49.5 -5.7 5.3 16.3 27.3 38.3

BerGenBio ASA 41.7 Oxford BioMedica Plc (United Kingdom) 36.3

MorphoSys AG 28.3 MorphoSys AG 25.3 Bavarian Nordic A/S 19.6 Nordic Nanovector ASA 15.3 Lonza Group AG 17.1 Bavarian Nordic A/S 12.7 Novozymes A/S 1.8 Peer Group Average 12.5 Genus Plc -1.2 Genus Plc 6.7 Peer Group Average -2.2 Lonza Group AG 3.5 Nordic Nanovector ASA -7.0

Abcam PLC -20.2 Abcam PLC 0.5

Oxford BioMedica Plc (United Kingdom) -100.0 Novozymes A/S -0.1

-122.0 -79.1 -36.2 6.6 49.5 -5.7 5.3 16.3 27.3 38.3

Health Care/Biotechnology Price: 1,560.00 GBX Report Date: September 24, 2021 Abbreviations: CAGR - Cumulative annual growth rate. EBIT - Earnings before interest and taxes. EBITDA - Earnings before interest, taxes, depreciation & amortization. LFY - Last fiscal year M - Million LON - London Stock Exchange

Definitions: Market Value - Weekly Price times latest Shares Outstanding times any applicable ADR factor. Revenue - Sum of the last four quarters of Revenues. Revenue Per Share - Sum of the last four quarters of Total Revenue divided by Weighted Average Shares Outstanding. Operating EPS LFY - EPS excluding non-recurring, non-operating items, fiscal year aligned TTM value. 60-Day Average Volume (000) - The average of the last 60 daily volume values in thousands of shares. Price 52-Week High - The high closing price from the last 52 weeks of daily closing prices. Price 52-Week Low - The low closing price from the last 52 weeks of daily closing prices. Price / 52-Week High - Latest price divided by the high price from the past 52 weeks of daily closing prices. Price / 52-Week Low - Latest price divided by the low price from the past 52 weeks of daily closing prices. 50-Day Average Price - Mean of last 50 daily closing prices. 200-Day Average Price - Mean of last 200 daily closing prices. Price / 50-Day Average Price - Latest closing price divided by mean of last 50 daily closing prices, as a percentage. Price / 200-Day Average Price - Latest closing price divided by mean of last 200 daily closing prices, as a percentage. Relative Strength Index - Relative Strength Index or RSI measures the magnitude of gains over a given time period against the magnitude of losses over that period. The equation is RSI = 100 - 100 / (1 + RS) where RS = (total gains / n) / (total losses / n) and n = number of RSI periods. In this item, 14 days is used and one year of daily prices are considered. A value of 30 or below may imply oversold and 70 or above may imply overbought. Price Volatility - The standard deviation of the last 20 days of daily closing prices. Sharpe Ratio - The 5 year average of the excess monthly return over the risk - free rate(1 - month T - bill) over the 5 year standard deviation of the same series. Sortino Ratio - The same calculation as the Sharpe Ratio but with positive excess returns set to zero for the standard deviation denominator, so only negative volatility weighs in. Dividends Per Share TTM - Sum of the last four quarters of Dividends Per Share. Payout Ratio - Dividends Per Share TTM divided by Operating EPS TTM. Dividend Yield TTM % - Sum of the last four quarter of Dividends Per Share divided by Weekly Price. EBITDA - Sum of the last four quarters of EBITDA (Operating Income + Depreciation & Amortization). Free Cash Flow - Sum of the last four quarters Net Cash from Operations minus Capital Expenditures (Purchase of Property, Plant & Equipment), from the Cash Flow Statement. Book Value Per Share - Total Common Equity last quarter divided by Shares Outstanding last quarter. Gross Margin % - Sum of the last four quarters Gross Profit divided by the sum of the last four quarters Revenues. EBITDA Margin % - Sum of the last four quarters EBITDA divided by the sum of the last four quarters Revenues. Pre-Tax Margin % - Sum of the last four quarters of Earnings Before Taxes divided by sum of the last four quarters Revenues. Net Profit Margin % - Sum of the last four quarters of Operating EPS divided by sum of the last four quarters Revenues Per Share. Return on Equity % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Book Value. Return on Capital % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Total Capital Per Share. Return on Assets % - Sum of the last four quarters of Operating EPS divided by the average of the last four quarters Total Assets Per Share. Price / EPS TTM - Weekly Price divided by the sum of the last four quarters of Operating EPS (capped at 99.9). Price / Sales - Weekly Price divided by Revenues Per Share TTM. Price / Book Value - Weekly Price divided by Book Value Per Share last quarter. Book Value Per Share is Total Common Equity last quarter divided by Shares Outstanding last quarter (capped at 49.9). Free Cash Flow Yield % - Free Cash Flow Per Share TTM divided by Weekly Price. Enterprise Value - Market Value plus Total Debt last year plus Preferred Equity last year minus Cash & Cash Equivalents last year. Enterprise Value / Sales - Enterprise Value divided by the sum of the last four quarters of Revenue. Enterprise Value / EBITDA - Enterprise Value divided by EBITDA TTM. Enterprise Value / EBIT - Enterprise Value divided by trailing four quarters of Operating Income. Enterprise Value / Free Cash Flow- Enterprise Value divided by the sum of the last four quarters of Free Cash Flow. Russell 1000 Index - The largest 1,000 stocks by market cap, the index comprehensively covers the US large cap universe. EPS 5-Year Growth Rate % is capped at 999.9%. Revenue 5-Year Growth Rate % is capped at 999.9%.

Health Care/Biotechnology Price: 1,560.00 GBX Report Date: September 24, 2021

Disclaimer:

© 2021 London Stock Exchange Group plc and its applicable group undertakings (the “LSE Group”). The LSE Group includes (1) FTSE International Limited (“FTSE”), (2) Frank Russell Company (“Russell”), (3) FTSE Global Debt Capital Markets Inc. and FTSE Global Debt Capital Markets Limited (together, “FTSE Canada”), (4) MTSNext Limited (“MTSNext”), (5) Mergent, Inc. (“Mergent”), (6) FTSE Fixed Income LLC (“FTSE FI”) and (7) The Yield Book Inc (“YB”). All rights reserved.

FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB. “FTSE®”, “Russell®”, “FTSE Russell®”, “MTS®”, “FTSE4Good®”, “ICB®”, “Mergent®”, “The Yield Book®” and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of the LSE Group or their respective licensors and are owned, or used under licence, by FTSE, Russell, MTSNext, FTSE Canada, Mergent, FTSE FI, YB. FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator.

All information is provided for information purposes only. All information and data contained in this publication is obtained by the LSE Group, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of the LSE Group nor their respective directors, officers, employees, partners or licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or of results to be obtained from the use of FTSE Russell indexes or data or the fitness or suitability of the FTSE Russell indexes or data for any particular purpose to which they might be put. Any representation of historical data accessible through FTSE Russell indexes or data is provided for information purposes only and is not a reliable indicator of future performance.

No responsibility or liability can be accepted by any member of the LSE Group nor their respective directors, officers, employees, partners or licensors for (a) any loss or damage in whole or in part caused by, resulting from, or relating to any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of the LSE Group is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.

No member of the LSE Group nor their respective directors, officers, employees, partners or licensors provide investment advice and nothing contained in this document or accessible through FTSE Russell indexes or data, including statistical data and industry reports, should be taken as constituting financial or investment advice or a financial promotion.

No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the applicable member of the LSE Group. Use and distribution of the LSE Group data requires a licence from FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB, and/or their respective licensors.